GenVec - GNVC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GenVec - GNVC

GNVC 7.193

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	9/18/2015 9:06:57 PM
	of 106

June... GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines GAITHERSBURG, Md., June 3, 2015 /PRNewswire/ -- GenVec, Inc. ( NASDAQ: GNVC) today announced a multi-faceted collaboration with Dr. David T. Curiel and his team from the School of Medicine at Washington University at St. Louis (WUSTL). Dr. Curiel is the director of the Biologic Therapeutic Center and the Cancer Biology Division within the Department of Radiation Oncology. Under the collaboration, GenVec and the WUSTL team will create modified versions of GenVec's gorilla adenovectors that incorporate specialized targeting antibodies on the surface of the vectors. These antibodies are produced only by camels, alpacas and other camelids and are smaller and more stable in intracellular environments than their mouse or human counterparts. The ultimate goal of this collaboration will be to create highly targeted therapeutics and vaccines.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next